Q-omics provides the consensus-scored ERICH6B profile across patient tissues and cancer cell-line models. ERICH6B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ERICH6B is differentially expressed in 11, with the highest sampling consensus in CHOL. Additionally, ERICH6B RNA expression shows 19,122 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, CHOL, and THYM as cancer lineages where ERICH6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERICH6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERICH6B survival associations across molecular data types. ERICH6B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERICH6B RNA expression–survival associations across cancer types. High ERICH6B expression shows unfavorable associations in KIRC, UVM and CESC, but favorable associations in PAAD, UCS and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ERICH6B RNA expression.
This table summarizes ERICH6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for ERICH6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERICH6B shows lower tumor expression in UCEC and higher tumor expression in CHOL, COAD, HNSC, KIRC and READ. The CHOL box plot shows higher ERICH6B RNA expression in tumor versus normal tissue (log2 FC = +0.301, t-test p = .022).
This table shows molecular features associated with ERICH6B in patient tissues and cancer cell lines. In patient samples, ERICH6B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ERICH6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
